1. Introduction
===============

Esophageal cancer (EC) is one of the most common and lethal cancers worldwide. The majority of patients die within 1 year of diagnosis, and only 8% to 20% of patients are alive at 5 years.^\[[@R1]\]^ Strategies to improve the outcome of EC have focused on multimodality treatment, including surgery, chemotherapy, and radiotherapy.^\[[@R2],[@R3]\]^ Although current practice incorporating chemotherapy or radiation into the treatment protocol, surgical resection may remain the only chance for curing this disease. Complete surgical resection with radical lymphadenectomy also provides accurate staging information, which is important for outcome prediction and treatment decision making. An effective and rational staging system of EC is the essential prerequisite to determine the appropriate treatments and predict long-term survival.^\[[@R4]\]^

The confirmed prognostic indicators include histological grading, tumor differentiation, tumor (T), nodal metastases (N), and metastasis (M) classification, whereas the current TNM classification system does not consider the tumor length in the staging and classification scheme for patients with esophageal carcinoma.^\[[@R5],[@R6]\]^ In recent years, more and more studies have observed that tumor length was an independent prognostic predictor. Bolton et al^\[[@R7]\]^ analysis 133 patients with EC who received surgery resection and found tumor length was a risk factor for long-term survival and lymph node involvement in early stage patients. Wang et al^\[[@R8]\]^ retrospectively reviewed 582 patients with EC who underwent curative resection and demonstrated that tumor length could have a significant impact on the overall survival (OS) and disease-free survival (DFS). Our early studies implied that tumor length was an important prognostic factor on both the OS and cancer-specific survival (CSS).^\[[@R9],[@R10]\]^ However, the prognostic role of tumor length in EC is still controversial. Kahn et al^\[[@R11]\]^ indicated that tumor length was not a prognostic factor in N0 EC patients. Hence, the aim of this study was to use meta-analysis to evaluate the prognostic value of tumor length for survival in patients with EC patients. To the best of our knowledge, this is the first meta-analysis to investigate the prognostic role of in patients with EC.

2. Methods
==========

2.1. Study registration
-----------------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines will be followed in the protocol.^\[[@R12]\]^ This systematic review and meta-analysis has been registered on PROSPERO with registration number: CRD CRD42018106851. Ethical approval is not required because this is a study based on aggregate data and did not involve humans.

### 2.1.1. Data sources and search strategy

The PubMed, Embase, and Web of Science databases will be searched for relevant articles. Both full text and MeSH search for keywords were used. The reference lists and related articles in each identified publication were also reviewed for potential studies. In addition, the reference lists of relevant publication were also reviewed to avoid missing relevant studies.

Search strategy of PubMed was as follows: (tumor length) OR (tumor size); (esophageal neoplasm) OR (esophageal cancer) OR (esophageal carcinoma) OR (EC); (prognosis) OR (survival); Step 1 AND step 2 AND step 3.

2.2. Inclusion and exclusion criteria
-------------------------------------

Articles will be included if they meet the following criteria: retrospective or prospective studies; exploring the relationship between tumor length and clinicopathological features or prognosis of EC; hazard ratios (HRs) and 95% CIs for the associations between tumor length and survival outcomes \[OS and DFS/progression-free survival (PFS)/relapse-free survival (RFS)/CSS\] were reported; and studies published in English.

Articles will be excluded if they meet the following criteria: abstracts, letters, editorials, reviews, or case reports; studies were not available in English; studies had overlapping or repeat data; studies concerned non-human or non-clinical research; and studies did not present the cut-off value for tumor length.

2.3. Data extraction and quality assessment
-------------------------------------------

### 2.3.1. Selection of studies

Two reviewers (XZ and YW) will select the included studies and extract relevant data independently from the studies. Any disagreement will be solved by group discussion. If necessary, the third reviewer (YJ) will be consulted. The selection process will be summarized according to PRISMA flow diagram (Fig. [1](#F1){ref-type="fig"}).
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### 2.3.2. Data extraction and management

Two researchers (XZ and YW) reviewed the eligible articles independently. Any disagreement will be solved by consensus or an arbiter (YJ). HRs were extracted preferentially from multivariable analyses where available. Otherwise, HRs from univariate analyses were extracted. The data were obtained directly from individual articles or were calculated from indirect data.^\[[@R13]\]^ In addition, other clinic pathologic parameters were extracted using a unified form including author, year of publication, country of origin, total number of patients, age, sex, follow-up time, operation strategy, TNM stage, and cut-off value of tumor length.

### 2.3.3. Assessment of quality in included studies

The quality of the included studies was assessed through the Newcastle-Ottawa Quality Assessment Scale (NOS) for no randomized studies, which consists of 3 parts: selection (0--4 points), comparability (0--2 points), and outcome assessment (0--3 points). The maximum score is 9 points and NOS scores ≥7 were assigned as high-quality studies.^\[[@R14]\]^ Two reviewers (XZ and YW) will independently assess the quality of each study and any conflicts disagreements in quality assessment were resolved by joint discussion.

### 2.3.4. Measures of prognosis

Pooled HRs and 95% CIs were used to analyze the relationship between tumor length and prognosis (OS or DFS/PFS/RFS/CSS). HRs were extracted preferentially from multivariable analyses where available. Otherwise, HRs from univariate analyses were extracted. The data were obtained directly from individual articles or were calculated from indirect data using the methods proposed by Tierney et al.^\[[@R13]\]^

### 2.3.5. Management of missing data

Some data are missing in several included studies, so we will contact the corresponding author to request any inadequate and missing data by E-mail. If the data are still incomplete, we will perform data synthesis through available information and address the potential impact of missing data on the pooled results in the discussion parts.

### 2.3.6. Assessment of heterogeneity

Assessment of heterogeneity between the included studies will be conducted to evaluate the feasibility of meta-analysis. The Cochran Q test and Higgins *I*^2^ method will be used to assess the heterogeneity.^\[[@R15]\]^ A *P* \< .05 for Q test or *I*^2^ \> 50% for *I*^2^ test suggested significant heterogeneity in the literature, whereas a *P* \> .05 for *Q* test or *I*^2^ \< 50% for *I*^2^ test indicated no heterogeneity. In cases of substantial heterogeneity, we will perform subgroup analysis to explore the potential causes.

### 2.3.7. Data synthesis

All the statistical analyses will be performed using STATA statistical software version 14.0 (STATA, College Station, TX). The pooled HR and 95% CIs will be used to assess the prognostic role of tumor length in EC patients. A *P* \< .10 for *Q* test or *I*^2^ \> 50% for *I*^2^ test suggested significant heterogeneity in the literature and a random-effect model (DerSimonian-Laird method) was used.^\[[@R16]\]^ Otherwise, the fixed-effects model (Mantel-Haenszel method) was adopted.^\[[@R17]\]^ In addition, subgroup analysis and sensitivity analysis will also be conducted to explain the possible heterogeneity. All *P* values were 2 sided. A *P* \< .05 was considered statistically significant.

### 2.3.8. Subgroup analysis

If the necessary data are available, subgroup analysis will be conducted to determine the possible factors that may influence the results: different nationality of patients; different histology type of EC; different treatment strategies; different statistical analysis methods; and different cut-off values.

### 2.3.9. Sensitivity analysis

Sensitivity analysis will be conducted by omitting each single study every time to see the influence of the individual dataset on the pooled HRs. The results will not be substantially changed when any study is excluded if the pooled HRs are robust.

### 2.3.10. Publication bias

Begg funnel plot and Egger test linear regression test will be conducted to evaluate the publication bias of the included studies.^\[[@R18],[@R19]\]^ If publication bias is detected (*P* \< .05 is considered statistically significant), we will perform the "trim and fill" test for further analysis.

3. Discussion
=============

EC is one of the deadliest malignances worldwide with a poor 5-year survival rate of approximately 20%.^\[[@R1]\]^ With improvements in the treatment techniques, the strategies have focused on multimodality treatment, including surgery, chemotherapy, and radiotherapy. Complete surgical resection with radical lymphadenectomy could provide accurate TNM staging information. The rational staging system for EC is critical to determine the appropriate management and predict long-term survival.^\[[@R4]\]^ In the latest American Joint Committee on Cancer staging system for EC, histological grading and tumor location as well as depth of esophageal wall invasion (T classification), lymph node involvement (N classification), and distant metastasis (M classification) are regarded as prognostic factors.^\[[@R5]\]^ However, heterogeneous clinical courses are frequently observed even within the same tumor stage. So many other clinicopathological factors predicting the outcome of cancer patient have been investigated over the past decades.^\[[@R20],[@R21]\]^

Nowadays more and more studies have focused the prognostic role of tumor length in EC patients. Unfortunately, these results still remain controversial. Wang et al^\[[@R8]\]^ evaluated 582 patients with esophageal squamous cell carcinoma who underwent surgical resection and indicated that tumor length could impact the OS. Tumor length may provide additional prognostic information to the current TNM staging system. Yendamuri et al^\[[@R22]\]^ and Song et al^\[[@R23]\]^ demonstrated similar results. However, Kahn et al^\[[@R11]\]^ indicated that tumor length was not a prognostic factor in N0 EC patients. To better understand the impact of tumor length on survival in EC patients, we conducted the meta-analysis to provide more objective and accurate proofs of the relations between tumor length and the prognosis of patients with EC.

Several limitations need to be addressed in our review. Firstly, only studies published in English will be included which may cause the publication bias in our study. Secondly, different resources of patients and pathological types, different treatment strategies, and duration of follow-up, different cut-off value of tumor length and statistic methods, will increase the heterogeneity in our study. Although we will conduct Begg funnel plot and Egger test to evaluate the publication bias and undertake the subgroup analysis to explain the heterogeneity, these limitations may hinder the application of the ratios in the clinical work. Further meta-analyses including additional studies and increased sample sizes are needed to correct for publication bias and heterogeneity and improve the accuracy.
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